Keith Woods - 13 Jun 2024 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Reporting relationship: Director
Issuer ticker: RCKT
Reported as of: 13 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Jun 2024, 16:10:26 UTC
Prior SEC filing: 14 Jun 2024
Next SEC filing: 16 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Martin Wilson, as attorney-in-fact

Key filing fact

Keith Woods filed Form 4 for ROCKET PHARMACEUTICALS, INC. (RCKT) on 20 Jun 2024.

Key facts

This page summarizes Keith Woods's Form 4 filing for ROCKET PHARMACEUTICALS, INC. (RCKT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 20 Jun 2024, 16:10.

Change

Previous filing in this sequence was filed on 14 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RCKT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +23,944
Change %
Price: $0.000000
Shares after: 23,944
Date: 13 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 23,944
Exercise price: $22.86
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option represents a right to purchase a total of 23,944 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2025.